User:Alexander Lee Schmidt/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 4: | Line 4: | ||
==Structure== | ==Structure== | ||
The main ingredient of NitroDura is 1,2,3-propanetriol trinitrate a/k/a <scene name='74/745476/Nitroglycerinmolecule/1'>Nitroglycerin</scene>. Nitroglycerin is molecule that when broken down to nitric oxide binds to protein domains found in smooth muscle. These binding domains are often found in the form of dimers that require multiple NO molecules to bind as seen in <scene name='74/745476/2o0c_molecule/2'>Nitric Oxide bound to the domain of Nostoc cyanbacterial protein</scene>. The Nitric Oxide is often buried deep within the protein, that in conjunction with other molecular interactions triggers structural changes that activate proteins to serve their specific functions (<scene name='74/745476/2o0c_molecule/2'>NO and CO activating soluble guanylyl cyclase via a heme pivot-bend mechanism.</scene>). In humans, NO binds to protein domains in this same fashion, as seen in <scene name='74/745476/Guanylate_cyclase/1'>Heterodimeric Catalytic Domain of Wild-type Human Soluble Guanylate Cyclase </scene>. | The main ingredient of NitroDura is 1,2,3-propanetriol trinitrate a/k/a <scene name='74/745476/Nitroglycerinmolecule/1'>Nitroglycerin</scene>. Nitroglycerin is molecule that when broken down to nitric oxide binds to protein domains found in smooth muscle. These binding domains are often found in the form of dimers that require multiple NO molecules to bind as seen in <scene name='74/745476/2o0c_molecule/2'>Nitric Oxide bound to the domain of Nostoc cyanbacterial protein</scene>. The Nitric Oxide is often buried deep within the protein, that in conjunction with other molecular interactions triggers structural changes that activate proteins to serve their specific functions (<scene name='74/745476/2o0c_molecule/2'>NO and CO activating soluble guanylyl cyclase via a heme pivot-bend mechanism.</scene>). In humans, NO binds to protein domains in this same fashion, as seen in <scene name='74/745476/Guanylate_cyclase/1'>Heterodimeric Catalytic Domain of Wild-type Human Soluble Guanylate Cyclase </scene>. | ||
- | |||
==Medication Details== | ==Medication Details== | ||
The medical delivery method for Nitroglycerin can come in the form of tablets (that dissolved under the tongue, or in the cheek), topical ointments, or patches <ref name="citation2">Tryzelaar, Dr. "Nitroglycerin (NTG)." Nitroglycerin (NTG). N.p., n.d. Web. 16 Oct. 2016”</ref>. Nitro-Dur delivers nitroglycerin to the body in the form of an acrylic patch <ref name="citation1">"NITRO-DUR® TRANSDERMAL DELIVERY SYSTEM." N.p., 3 Oct. 2014. Web. 16 Oct. 2016 </ref>. The NitroDur patch itself is composed of four layers that each serve a specific function in delivering an adequate dosage of nitroglycerin to the body. The exposed outermost layer of the patch is made up of aluminized plastic that is impermeable to nitroglycerin. This material prevents nitroglycerin from escaping through the back of the patch and directs the molecule to diffuse in the desired direction of toward the skin. The next layer consists of the actual nitroglycerin adsorbed in a mixture of lactose, colloidal silicon dioxide, and silicone medical fluid. The third layer is an ethylene-vinyl acetate copolymer layer that is selectively permeable to the desired nitroglycerin molecule. The final layer that functions to adhere the patch to the skin is composed of hypoallergenic silicone. <ref>"Transderm Nitro (Nitroglycerin): Side Effects, Interactions, Warning, Dosage & Uses." RxList. N.p., 30 Mar. 2009. Web. 12 Nov. 2016.</ref> | The medical delivery method for Nitroglycerin can come in the form of tablets (that dissolved under the tongue, or in the cheek), topical ointments, or patches <ref name="citation2">Tryzelaar, Dr. "Nitroglycerin (NTG)." Nitroglycerin (NTG). N.p., n.d. Web. 16 Oct. 2016”</ref>. Nitro-Dur delivers nitroglycerin to the body in the form of an acrylic patch <ref name="citation1">"NITRO-DUR® TRANSDERMAL DELIVERY SYSTEM." N.p., 3 Oct. 2014. Web. 16 Oct. 2016 </ref>. The NitroDur patch itself is composed of four layers that each serve a specific function in delivering an adequate dosage of nitroglycerin to the body. The exposed outermost layer of the patch is made up of aluminized plastic that is impermeable to nitroglycerin. This material prevents nitroglycerin from escaping through the back of the patch and directs the molecule to diffuse in the desired direction of toward the skin. The next layer consists of the actual nitroglycerin adsorbed in a mixture of lactose, colloidal silicon dioxide, and silicone medical fluid. The third layer is an ethylene-vinyl acetate copolymer layer that is selectively permeable to the desired nitroglycerin molecule. The final layer that functions to adhere the patch to the skin is composed of hypoallergenic silicone. <ref>"Transderm Nitro (Nitroglycerin): Side Effects, Interactions, Warning, Dosage & Uses." RxList. N.p., 30 Mar. 2009. Web. 12 Nov. 2016.</ref> | ||
- | |||
== Function == | == Function == | ||
Line 25: | Line 23: | ||
===Chronic Achilles Tendinopathy=== | ===Chronic Achilles Tendinopathy=== | ||
Chronic Achilles Tendinopathy is characterized by pain in the achilles tendon that is caused by tendon degradation <ref>Chronic Achilles Tendon Injury: An Overview." Hospital for Special Surgery. N.p., 1 June 2011. Web. 30 Oct. 2016 </ref>. A study conducted at an Australian University Hospital looked at the effect of topical glyceryl trinitrate (in the form of a NitroDur patch) on pain management and symptoms in chronic noninsertional Achilles tendinopathy. Study participants were given an active transdermal NitroDur patch, which delivered 1.25 mg of glyceryl trinitrate over 24 hours, or a placebo treatment patch. Over the course of 24 weeks, participants applied one fourth of the NitroDur patch to their most painful site on their body. Study results showed that the NitroDur patch was more effective than placebo in reducing pain caused by chronic noninsertional Achilles tendonitis <ref>PMID: 15782065 </ref>. | Chronic Achilles Tendinopathy is characterized by pain in the achilles tendon that is caused by tendon degradation <ref>Chronic Achilles Tendon Injury: An Overview." Hospital for Special Surgery. N.p., 1 June 2011. Web. 30 Oct. 2016 </ref>. A study conducted at an Australian University Hospital looked at the effect of topical glyceryl trinitrate (in the form of a NitroDur patch) on pain management and symptoms in chronic noninsertional Achilles tendinopathy. Study participants were given an active transdermal NitroDur patch, which delivered 1.25 mg of glyceryl trinitrate over 24 hours, or a placebo treatment patch. Over the course of 24 weeks, participants applied one fourth of the NitroDur patch to their most painful site on their body. Study results showed that the NitroDur patch was more effective than placebo in reducing pain caused by chronic noninsertional Achilles tendonitis <ref>PMID: 15782065 </ref>. | ||
- | |||
===Raynaud’s Phenomenon=== | ===Raynaud’s Phenomenon=== | ||
The Raynaud's pehnomenon occurs due to vasoconstriction of the capillaries, veins, and arteries in external digits <ref name="citation2"> <ref>PMCID: PMC2860448</ref>. Symptoms of raynaud’s involves the fingers or toes turning pale, becoming numb, and then becoming purple or blue. These symptoms result from attacks that can are characterized by spasms in the small blood vessels of the fingers and toes <ref>Haythornthwaite, Jenifer, Dr., and Fredrick Wigley, Dr. "Raynaud's, Finger and Skin Care." Scleroderma Education Program Chapter 2 Raynaud’s, Finger and Skin Care (n.d.): n. pag. Web. 16 Oct. 2016 </ref>. Patients who have been diagnosed with Raynaud’s phenomenon will occasionally need pharmacologic therapy. While the nitro-dur patch is not specifically used, topical nitroglycerin can be prescribed to these patients and decreases the occurrence and severity of vasospastic episodes <ref name="citation2"> </ref>. Nitroglycerin does this by expanding the blood vessels allowing blood to better circulate <ref name="citation3"> </ref>. | The Raynaud's pehnomenon occurs due to vasoconstriction of the capillaries, veins, and arteries in external digits <ref name="citation2"> <ref>PMCID: PMC2860448</ref>. Symptoms of raynaud’s involves the fingers or toes turning pale, becoming numb, and then becoming purple or blue. These symptoms result from attacks that can are characterized by spasms in the small blood vessels of the fingers and toes <ref>Haythornthwaite, Jenifer, Dr., and Fredrick Wigley, Dr. "Raynaud's, Finger and Skin Care." Scleroderma Education Program Chapter 2 Raynaud’s, Finger and Skin Care (n.d.): n. pag. Web. 16 Oct. 2016 </ref>. Patients who have been diagnosed with Raynaud’s phenomenon will occasionally need pharmacologic therapy. While the nitro-dur patch is not specifically used, topical nitroglycerin can be prescribed to these patients and decreases the occurrence and severity of vasospastic episodes <ref name="citation2"> </ref>. Nitroglycerin does this by expanding the blood vessels allowing blood to better circulate <ref name="citation3"> </ref>. | ||
- | |||
</StructureSection> | </StructureSection> |
Revision as of 21:38, 12 November 2016
NitroDur
|
delete these later
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Tryzelaar, Dr. "Nitroglycerin (NTG)." Nitroglycerin (NTG). N.p., n.d. Web. 16 Oct. 2016”
- ↑ "NITRO-DUR® TRANSDERMAL DELIVERY SYSTEM." N.p., 3 Oct. 2014. Web. 16 Oct. 2016
- ↑ "Transderm Nitro (Nitroglycerin): Side Effects, Interactions, Warning, Dosage & Uses." RxList. N.p., 30 Mar. 2009. Web. 12 Nov. 2016.
- ↑ Mayer, B., and Beretta, M. (2008) The enigma of nitroglycerin bioactivation and nitrate tolerance. News, views, and troubles. Br. J. Pharmacol. 155, 170-184
- ↑ 5.0 5.1 Lang, Barbara S., Antonius Cf Gorren, Gustav Oberdorfer, M. Wenzl, Cristina M. Furdui, Leslie B. Poole, Bernd Mayer, and Karl Gruber. "Vascular Bioactivation of Nitroglycerin: Reaction Mechanism Revealed by Crystal Structure of Aldehyde Dehydrogenase-2." BMC Pharmacology and Toxicology BMC Pharmacol Toxicol 13.Suppl 1 (2012): n. pag. Web. 1 Nov. 2016.
- ↑ "Nitrostat (Nitroglycerin) Drug Information: Clinical Pharmacology - Prescribing Information at RxList." RxList. N.p., n.d. Web. 30 Oct. 2016.
- ↑ 7.0 7.1 7.2 Heer T, Reiter S, Trissler M, Hofling B, von Knobelsdorff-Brenkenhoff F, Pilz G. Effect of Nitroglycerin on the Performance of MR Coronary Angiography. J Magn Reson Imaging. 2016 Oct 12. doi: 10.1002/jmri.25483. PMID:27731913 doi:http://dx.doi.org/10.1002/jmri.25483
- ↑ Chronic Achilles Tendon Injury: An Overview." Hospital for Special Surgery. N.p., 1 June 2011. Web. 30 Oct. 2016
- ↑ Hunte G, Lloyd-Smith R. Topical glyceryl trinitrate for chronic Achilles tendinopathy. Clin J Sport Med. 2005 Mar;15(2):116-7. PMID:15782065
- ↑ Haythornthwaite, Jenifer, Dr., and Fredrick Wigley, Dr. "Raynaud's, Finger and Skin Care." Scleroderma Education Program Chapter 2 Raynaud’s, Finger and Skin Care (n.d.): n. pag. Web. 16 Oct. 2016